In Vitro Cancer Models: A Closer Look at Limitations on Translation
Open Access
- 7 April 2022
- journal article
- review article
- Published by MDPI AG in Bioengineering
- Vol. 9 (4) , 166
Abstract
In vitro cancer models are envisioned as high-throughput screening platforms for potential new therapeutic discovery and/or validation. They also serve as tools to achieve personalized treatment strategies or real-time monitoring of disease propagation, providing effective treatments to patients. To battle the fatality of metastatic cancers, the development and commercialization of predictive and robust preclinical in vitro cancer models are of urgent need. In the past decades, the translation of cancer research from 2D to 3D platforms and the development of diverse in vitro cancer models have been well elaborated in an enormous number of reviews. However, the meagre clinical success rate of cancer therapeutics urges the critical introspection of currently available preclinical platforms, including patents, to hasten the development of precision medicine and commercialization of in vitro cancer models. Hence, the present article critically reflects the difficulty of translating cancer therapeutics from discovery to adoption and commercialization in the light of in vitro cancer models as predictive tools. The state of the art of in vitro cancer models is discussed first, followed by identifying the limitations of bench-to-bedside transition. This review tries to establish compatibility between the current findings and obstacles and indicates future directions to accelerate the market penetration, considering the niche market.Keywords
Funding Information
- CCDR-N - Northern Regional Development and Coordination Commission; NORTE2020; FEDER - Fundo Europeu de Desenvolvimento Regional (FROnTHERA-NORTE-01-0145-FEDER-000023)
- European Union Framework Programme for Research and Innovation Horizon 2020 (nº 668983 — FoReCaST)
- Fundação para a Ciência e a Tecnologia (PD/BD/143050/2018, PTDC/BTM-ORG/28168/2017)
This publication has 72 references indexed in Scilit:
- The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and MenClinical Cancer Research, 2012
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survivalDrug Discovery Today, 2012
- Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug Discovery, 2012
- The productivity crisis in pharmaceutical R&DNature Reviews Drug Discovery, 2011
- Mouse models of advanced spontaneous metastasis for experimental therapeuticsNature Reviews Cancer, 2011
- Inflammation, Aging, and Cancer: Tumoricidal Versus Tumorigenesis of ImmunityCell Biochemistry and Biophysics, 2009
- Patents and Innovation in Cancer Therapeutics: Lessons from CellProThe Milbank Quarterly, 2002
- Whole-istic BiologyScience, 2002
- Public Research and Private Development: Patents and Technology Transfer in Government-Sponsored ResearchVirginia Law Review, 1996
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889